KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.

Masataka Kuwana, Tomoki Ito, Shugo Kowata, Yoshihiro Hatta, Katsumichi Fujimaki, Kensuke Naito, Shingo Kurahashi, Toshiya Kagoo, Kazuki Tanimoto, So Saotome, Yoshiaki Tomiyama, R788-1301 Investigators

Br J Haematol 200(6) 802-811

PMID36470677
PMCID-
DOI10.1111/bjh.18582
发表日期2022-12-05
摘要

摘要

Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved for the treatment of chronic primary immune thrombocytopenia (ITP) in the United States, Canada and some European countries. We conducted a phase 3, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of fostamatinib in Japanese patients with primary ITP. Thirty-four patients were randomised to fostamatinib (n = 22) or placebo (n = 12) at 100-150 mg twice a day for 24 weeks. Stable responses (platelet ≥50 000/μl at ≥4 of the 6 visits from weeks 14 to 24) were observed in eight (36%) patients on fostamatinib and in none of the patients on placebo (p = 0.030). Overall responses (platelet ≥50 000/μl at ≥1 of the 6 visits from weeks 2 to 12) were seen in 10 (45%) patients on fostamatinib and in none of the patients on placebo (p = 0.006). Patients on fostamatinib required rescue medication less often and experienced fewer bleeding symptoms than patients on placebo. Adverse events observed were mild or moderate and were manageable. No new safety signals were identified in Japanese patients with ITP.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。